Latest Breaking News On - Phospholipid drug conjugate - Page 6 : comparemela.com

Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing - Cellectar Biosciences (NASDAQ:CLRB)

FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted

United statesClaire lacagninaCellectar biosciencesMonique kosseDrug administrationCompany seriesBliss bio healthExchange commissionOppenheimer coCellectar biosciences incRosalind advisorsSecond lineNantahala capitalNew drug applicationSeriese preferred stockCommon stock

Cellectar Reports Financial Results for Second Quarter 2023

FLORHAM PARK, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the.

United statesJarrod longcorMonique kosseJames carusoCellectar biosciencesCellectar biosciences incExchange commissionSociety of nuclear medicineDevelopment expenseTherapeutic area partnership oncologyRecent corporateNuclear medicineMolecular imaging annualTherapeutic area partnershipCash equivalentsAdministrative expense

Cellectar Biosciences: Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update

Cellectar Biosciences: Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJames carusoMonique kosseJarrod longcorCellectar biosciencesCellectar biosciences incDevelopment expenseSociety of nuclear medicineTherapeutic area partnership oncologyExchange commissionRecent corporateNuclear medicineMolecular imaging annualTherapeutic area partnershipCash equivalentsAdministrative expense

Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update

FLORHAM PARK, N.J., May 04, 2023 Cellectar Biosciences, Inc. , a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for. | May 4, 2023

United statesMonique kosseCellectar biosciencesJames carusoExchange commissionDevelopment expenseGlobenewswire incCellectar biosciences incEvents page of the companyRecent corporateCapital partnersAnnual conferenceAnnual healthcare conferenceEvents pageCash equivalentsAdministrative expense

Cellectar Biosciences Announces Shane Lea as Chief

FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused.

United statesJames carusoMonique kosseCellectar biosciencesShane leaAllos therapeuticsBachelor of business administrationLifesci advisorsImclone systemsCellectar biosciences incAbraxis bioscienceExchange commissionUniversity of louisiana monroeAventis oncologyBusiness administrationPhospholipid drug conjugate